联合18F-FDG PET与CT获得的乳腺影像参数可提高对Luminal/HER2阴性乳腺癌新辅助化疗后保乳手术的预测
回顾性纳入77例初始不适合保乳、因新辅助化疗前肿瘤缩小而接受治疗的Luminal/HER2阴性乳腺癌女性,于首程新辅助化疗前后行18F-FDG PET-CT。新辅助化疗后64%(49/77)行保乳手术、36%(28/77)行乳房切除术;以乳腺总体积496 cm3和代谢肿瘤体积变化-17.1%为阈值可将患者分为保乳概率29%、62%、82%的三组。
要点
- 乳房切除组乳腺总体积更低(p=0.002)、代谢肿瘤体积下降幅度更小(p=0.03)、SUVmax2更低(p=0.05)。
- 以乳腺总体积496 cm3与代谢肿瘤体积变化-17.1%为阈值,可将保乳概率分为29%、62%、82%三组(p=0.001)。
- 联合基线及首程新辅助化疗后18F-FDG PET-CT的肿瘤与乳腺影像特征,可能帮助评估保乳手术概率。
核心结论
- 对Luminal/HER2阴性乳腺癌患者,联合基线与首程新辅助化疗后18F-FDG PET-CT获得的肿瘤和乳腺影像特征,可能让医生评估保乳手术的概率。
研究设计与样本
- 回顾性纳入77例连续女性Luminal/HER2阴性乳腺癌患者,初始保乳手术不可行并因术前缩小肿瘤而接受新辅助化疗,于首程新辅助化疗前后行18F-FDG PET-CT检查。
关键影像表现/征象
- 乳房切除组乳腺总体积低于保乳组(p=0.002)。
- 乳房切除组代谢肿瘤体积下降幅度小于保乳组(p=0.03)。
- 乳房切除组SUVmax2低于保乳组(p=0.05)。
诊断标准与关键数值
- 以ROC曲线确定乳腺总体积最佳预测阈值为496 cm3、代谢肿瘤体积变化最佳预测阈值为-17.1%。
- 按上述两阈值将患者分为保乳概率低、中、高三组,分别为29%、62%、82%(p=0.001)。
- 新辅助化疗后64%(49/77)行保乳手术,36%(28/77)行乳房切除术。
临床应用与阅片要点
- 可结合基线及首程新辅助化疗后18F-FDG PET-CT测量的乳腺总体积、代谢肿瘤体积变化和SUVmax2评估保乳手术概率。
- 作者认为联合肿瘤与乳腺影像特征可能帮助医生评估Luminal/HER2阴性乳腺癌新辅助化疗后保乳手术的概率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
INTRODUCTION: The luminal/Human Epidermal growth factor Receptor 2 (HER2) negative subtype of breast cancer has low chemo-sensitivity. When neoadjuvant chemotherapy (NAC) is indicated in this subtype, before a possible breast-conserving surgery (BCS), it is more reasonable to target tumor shrinkage than complete pathological tumor response. We aimed to identify breast and tumor 18Fluoro-deoxy-glucose (18F-FDG) PET-CT scan imaging features for the early prediction of BCS after NAC in luminal/HER2 negative subtypes of breast cancer.
MATERIAL AND METHODS: Seventy-seven consecutive women with luminal/HER2-negative breast cancer for whom BCS was initially not feasible and NAC was prescribed, to decrease tumor size before surgery, were included retrospectively. An 18F-FDG PET-CT scan exam was performed before and after the first course of NAC.
RESULTS: After NAC, 36% (28/77) of women had a mastectomy and 64% (49/77) underwent BCS. Patients with a mastectomy had lower total breast volume (BVtotal) (p = 0.002), lower decrease in Δmetabolic tumor volume (ΔMTV) (p = 0.03) and lower SUVmax2 (p = 0.05). Using ROC Curve analyses to define the optimal predictive threshold of BVtotal (496 cm3) and ΔMTV (-17.1%), 3 subgroups of women with different odds of BCS after treatment were identified (p = 0.001): low, medium and high probability groups (respectively 29%, 62% and 82%).
CONCLUSIONS: For patients with Luminal/HER2 negative breast cancer, the combination of the imaging features of the tumor and the mammary gland, obtained with 18F-FDG PET-CT at baseline and after the first cycle of NAC, may allow the physician to evaluate the probability of BCS.
引用
- Grapin M, Coutant C, Riedinger JM, et al. Combination of breast imaging parameters obtained from 18F-FDG PET and CT scan can improve the prediction of breast-conserving surgery after neoadjuvant chemotherapy in luminal/HER2-negative breast cancer. Eur J Radiol. 2019. PMID: 30927964. doi:10.1016/j.ejrad.2019.02.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。